Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...

Johnson & Johnson (NYSE:JNJ) on Friday announced a Phase 3 trial win for its anti-inflammatory therapy Tremfya, highlighting ...

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

Secukinumab treatment reduces bone erosion volume and enhances partial healing of erosions in patients with psoriatic ...

Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U ...

While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

A new cohort study published in Journal of American Medical Association suggests that biologics targeting IL-12, IL-23, and ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Johnson & Johnson announced that the Tremfya Phase 3b APEX study achieved both its primary endpoint of reducing signs and symptoms and its ...

A new study explores gaps in how patients and physicians view psoriatic arthritis (PsA) and recommends ways for clinicians to ...